Clinical Trial Update: Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma [Phase 1]

View source ↗

Summary

Phase 1b/2 study evaluating Rogaratinib in combination with Atezolizumab in urothelial carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Rogaratinib

Snippet

Sponsor: Bayer | Conditions: Urothelial Carcinoma | Phase 1 | Status: COMPLETED | Results posted: 2025-04-09